XSTOS2M
Market cap754kUSD
Dec 23, Last price
0.01SEK
1D
0.00%
1Q
-56.52%
IPO
-99.96%
Name
S2Medical AB (publ)
Chart & Performance
P/E
—
P/S
1.20
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
27.73%
Rev. gr., 5y
36.05%
Revenues
7m
+49.27%
Net income
-23m
L-27.28%
CFO
-17m
L-41.28%
Profile
S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds. It offers INSTAQRETT, a sterile single use mechanical debridement tool; EPIPROTECT SafeStop for blood stilling; Instagraft, a single-use medical device for the treatment of chronic and complicated wounds; EPIPROTECT tissue substitutes; and washable, waterproof, and self-adhesive bandages under the INSTABIND brand name. The company also distributes Silverlon dressings that deliver silver ions into the wound. In addition, it operates wound healing center under the S2Clinic name. The company was founded in 2013 and is headquartered in Linköping, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 6,971 49.27% | 4,670 -39.35% | 7,700 -69.94% | ||||||
Cost of revenue | 2,540 | 100 | 13,194 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 4,431 | 4,570 | (5,494) | ||||||
NOPBT Margin | 63.56% | 97.86% | |||||||
Operating Taxes | 1,768 | 243 | |||||||
Tax Rate | 38.68% | ||||||||
NOPAT | 4,431 | 2,802 | (5,738) | ||||||
Net income | (22,707) -27.28% | (31,224) 53.64% | (20,323) 34.75% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 22,000 | 22,512 | (2,529) | ||||||
BB yield | -232.56% | -48.05% | 0.83% | ||||||
| Debt | |||||||||
Debt current | (231) | 208 | |||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1 | 1,772 | |||||||
Net debt | (1,517) | (3,954) | (9,271) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (16,520) | (28,131) | (19,665) | ||||||
CAPEX | (1,155) | (1,899) | (3,096) | ||||||
Cash from investing activities | (1,155) | (1,762) | (3,024) | ||||||
Cash from financing activities | 15,470 | 24,137 | 6,848 | ||||||
FCF | 9,389 | 9,884 | (5,300) | ||||||
| Balance | |||||||||
Cash | 1,517 | 3,723 | 9,479 | ||||||
Long term investments | |||||||||
Excess cash | 1,168 | 3,489 | 9,094 | ||||||
Stockholders' equity | (108,140) | (97,368) | (68,873) | ||||||
Invested Capital | 109,798 | 104,083 | 83,689 | ||||||
ROIC | 4.14% | 2.98% | |||||||
ROCE | 267.25% | 68.05% | |||||||
| EV | |||||||||
Common stock shares outstanding | 157,666 | 68,898 | 58,233 | ||||||
Price | 0.06 -91.18% | 0.68 -87.05% | 5.25 -34.38% | ||||||
Market cap | 9,460 -79.81% | 46,851 -84.68% | 305,723 -17.04% | ||||||
EV | 7,943 | 142,167 | 366,207 | ||||||
EBITDA | 6,165 | 6,488 | (4,000) | ||||||
EV/EBITDA | 1.29 | 21.91 | |||||||
Interest | 7,444 | 1,768 | 243 | ||||||
Interest/NOPBT | 168.00% | 38.68% | |||||||